• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch

Opinion
Video

Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.

Video content above is prompted by the following question:

  • Please discuss any other data in multiple myeloma released at EHA 2024 that you find noteworthy to share with colleagues.
  • Outside of EHA 2024 what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?
  • What can we look forward to through the end of the year and beyond?
Related Videos
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Paula Rodríguez-Otero, MD, PhD
Kelley L. Julian, PharmD, BCOP
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Paula Rodríguez-Otero, MD, PhD, Cancer Center Clínica Universidad de Navarra
Matias Sanchez, MD
Emilie Aschenbrenner, PharmD, BCOP, Froedtert Health and the Medical College of Wisconsin
Related Content
Defining the Comprehensive Role of the Oncology Pharmacist in Multiple Myeloma: Marcus Flores, PharmD, BCPS, BCOP

Defining the Comprehensive Role of the Oncology Pharmacist in Multiple Myeloma: Marcus Flores, PharmD, BCPS, BCOP

October 31st 2025
Article

Marcus Flores, PharmD, BCPS, BCOP, discusses the vital role of pharmacists in multidisciplinary cancer care, exploring collaboration, patient-centered strategies, and AI.

Read More

Multiple myeloma | Image Credit: © Dzmitry-stock.adobe.com

Venetoclax Combo Achieves Mixed Results in Relapsed/Refractory Multiple Myeloma

October 22nd 2025
Article

Venetoclax plus bortezomib and dexamethasone improved PFS in relapsed/refractory multiple myeloma, especially in patients with BCL2high disease.

Read More

Teclistamab | Image Credit: © luchschenF-stock.adobe.com

Teclistamab for R/R MM Effective and Safe When Administered in a Community Setting

September 24th 2025
Article

Teclistamab shows promising real-world effectiveness and safety in older adults with relapsed/refractory multiple myeloma (R/R MM), matching clinical trial outcomes.

Read More

While immunogenicity is often reduced, vaccination remains indispensable in multiple myeloma, according to the review. | Image credit: alernon77 - stock.adobe.com

Vaccination Remains Essential in Multiple Myeloma Despite Impaired Responses

September 4th 2025
Article

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

Read More

SWIFT-seq was able to successfully capture CTCs in 90% of patients with MGUS, SMM, and MM. | Image credit: luchschenF - stock.adobe.com

Novel Blood Test Could Transform Multiple Myeloma Diagnosis, Monitoring

August 23rd 2025
Article

Investigators believe the SWIFT-seq system holds potential to replace more invasive bone marrow biopsies.

Read More

Whether KRd‐based quadruplets will redefine the frontline standard now hinges on proving they can deliver deeper, longer‐lasting remissions without compromising safety. | Image credit: Dzmitry - stock.adobe.com

Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone

August 21st 2025
Article

Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.